The short version of triagonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-27. Anything still debated is marked as such rather than presented as settled.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
=== Shamanism, mestizos, and vegetalistas === Researchers like Peter Gow and Brabec de Mori argue that ayahuasca use indeed developed alongside the Jesuit missions after the 17th century. By examining the ícaros (ayahuasca-related healing chants), they found that the chants are always sung in Quechua (a lingua franca along the Jesuit and Franciscan missions in the region), no matter the linguistic background of the group, with similar language structures between different ícaros that are markedly different from other indigenous songs. Moreover, often the cosmology of ayahuasca often mirrors the Catholicism, with particular similarities in the belief that ayahuasca is thought to be the body of ayahuascamama that is imbibed as part of the ritual, like wine and bread are taken as being the body and blood of Jesus Christ during Christian Eucharist. Brabec de Mori called this "Christian camouflage" and suggested that rather than being a way for disguising the ayahuasca ritual, it suggests that practice evolved entirely within these contexts. Indeed, the colonial processes in Western Amazon are intrinsically related with the development of ayahuasca use in the last three centuries, as it promoted a deep reshape in traditional ways of life in the region. Many indigenous groups moved into the Missions, seeking protection from death and slavery promoted by the Bandeiras, inter-tribal violence, starvation and disease (smallpox).
=== Composition === Venom of the king cobra, produced by the postorbital venom glands, consists primarily of three-finger toxins (3FTx) and snake venom metalloproteinases (SVMPs). Of all the 3FTx, alpha-neurotoxins are the predominant and most lethal components when cytotoxins and beta-cardiotoxins also exhibit toxicological activities. It is reported that cytotoxicity of its venom varies significantly, depending upon the age and locality of an individual. Clinical cardiotoxicity is not widely observed, nor is nephrotoxicity present among patients bitten by this species, presumably due to the low abundance of the toxins. SVMPs are the second-most protein family isolated from the king cobra's venom, accounting from 11.9% to 24.4% of total venom proteins. The abundance is much higher than that of most cobras which is usually less than 1%. This protein family includes principal toxins responsible for vasculature damage and interference with haemostasis, contributing to bleeding and coagulopathy caused by envenomation of vipers. While there are such haemorrhagins isolated from the king cobra's venom, they only induce species-sensitive haemorrhagic and lethal activities on rabbits and hares, but with minimal effects on mice. Clinical pathophysiology of the king cobra's SVMPs has yet to be well studied, although its substantial quantity suggests involvement in tissue damage and necrosis as a result of inflammatory and proteolytic activities, which are instrumental for foraging and digestive purposes.
== Epidemiology and prevention == Selenium deficiency is uncommon, but regions in China, Europe, Russia, and New Zealand have low selenium levels in croplands and diet. The worldwide prevalence of selenium deficiency is however predicted to rise under climate change due to the loss of selenium from croplands. These diseases are most common in certain parts of China where the intake is low because the soil is extremely deficient in selenium. Studies in Jiangsu Province of China have indicated a reduction in the prevalence of these diseases by taking selenium supplements. In Finland, selenium salts are added to chemical fertilizers, as a way to increase selenium in soils. Dietary supplements may utilize sodium selenite, L-selenomethionine, or selenium-enriched yeast.
Sources: en.wikipedia.org
There is no cure for CMT, but its symptoms can be managed to maintain quality of life. Although no proven treatment can alter disease progression, physical and occupational therapy can help preserve muscle strength, flexibility, and mobility. Orthopedic devices like ankle-foot orthoses (AFOs) are commonly used to correct foot drop and improve gait. In some cases, surgical interventions may be necessary to straighten toes, lower arches, or fuse joints to enhance stability. Pain management may involve physical therapy, assistive devices, or medications for neuropathic pain. Drugs with gabapentin and pregabalin may be used for neuropathic pain. NSAIDs and SSRIs are also used for non-neuropathic pain related to skeletal deformities caused by CMT. Treadmill training in patients has especially been shown to improve symptoms associated with impaired walking and balancing over time. Strength training paired with creatine supplements can also help as it may compensate for weak distal muscles and help alleviate CMT-related chronic fatigue. Certain drugs, such as vincristine (a chemotherapy agent), should be avoided altogether in CMT patients due to their known toxicity to nerves. Regular follow-up with healthcare providers is essential to adapt care as the disease progresses.
Legio I I Armeniaca I Flavia Constantia (reliable Flavian): comitatensis unit under the command of the Magister militum per Orientis I Flavia Gallicana Constantia (reliable Flavian legion from Gallia): pseudocomitatensis under the command of the Magister Peditum per Gallias. The legion was founded by Constantius I Chlorus. The legions objective was to protect the Armorican coast and fight the Roman-British usurper, Allectus. I Flavia Martis (Flavian legion devoted to Mars): pseudocomitatensis. The legion was founded by Constantius Chlorus to fight Allectus. It was stationed in Gaul. I Flavia Pacis (Flavian legion of peace): comitatensis under the command of the Magister Peditum I Flavia Theodosiana: comitatensis. I Illyricorum (of the Illyrians): stationed at the Camp of Diocletian in Palmyra I Iovia (devoted to Jupiter): levied by Diocletian, stationed at Noviodunum in Scythia Minor I Isaura Sagittaria (archers from Isauria): pseudocomitatensis under the command of the Magister militum per Orientis I Iulia Alpina: pseudocomitatensis under the command of the Magister Peditum in Italy. It is unknown who founded the legion although it was probably Crispus or Constans. I Martia possibly based near modern Kaiseraugst. The Legion could have had the surname Victrix. The legion was probably founded by Diocletian. It also may have built forts in Valeria. I Maximiana Thaebanorum (the Thebans of Maximianus): comitatensis unit stationed near Thebes, Egypt, and probably fighting in the battle of Adrianople I Noricorum (of the Noricans): stationed in Noricum.
Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1. Zhong G, James MO, Smeltz MG, Jahn SC, Langaee T, Simpson P, Stacpoole PW. Drug Metab Dispos. 2018 Aug;46(8):1118-1128. doi: 10.1124/dmd.118.081810. Epub 2018 May 31. PMID: 29853471 Free PMC article. Glutathione transferase zeta1 (GSTZ1) catalyzes glutathione (GSH)-dependent dechlorination of dichloroacetate (DCA), an investigational drug with therapeutic potential in metabolic disorders and cancer. ...In samples from livers with the GSTZ1C variant, apparent enzyme kin … Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, Shuster JJ, Wagner DA, Stacpoole PW. Invest New Drugs. 2014 Jun;32(3):452-64. doi: 10.1007/s10637-013-0047-4. Epub 2013 Dec 3. PMID: 24297161 Free PMC article. Clinical Trial. All subjects completing at least 1 four week cycle remained clinically stable during this time and remained on DCA for an average of 75.5 days (range 26-312). CONCLUSIONS: Chronic, oral DCA is feasible and well-tolerated in patients with recurrent malignant gliomas …
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。